Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR oncogenic variants status confers therapeutic sensitivity to Bevacizumab, Erlotinib in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with erlotinib for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-small cell lung cancer with EGFR activating variants.
This statement is based on a regulatory approval from the Health Service Executive:
In combination with erlotinib is indicated for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous cell lung cancer with Epidermal Growth Factor (EGFR) activating mutations